Difference between revisions of "Team:CGU Taiwan/Proof"

Line 1: Line 1:
−
{{CGU_Taiwan}}
 
−
 
 
<html>
 
<html>
 +
<meta http-equiv="X-UA-Compatible" content="IE=edge">
 +
<meta name="viewport" content="width=device-width, initial-scale=1.0">
 +
<link rel="stylesheet" href="http://www.w3schools.com/lib/w3.css">
 +
<style>
 +
        #sideMenu
 +
        {
 +
        display:none; /* Disable the display of the annoying side main menu*/
 +
        }
 +
       
 +
        #top_title
 +
        {
 +
        display:none; /* Disable the annoying title*/
 +
        }
  
 +
#content { padding:0px; width:100%; margin-left:0%; margin-right:0%;}
 +
</style>
  
−
<h3>★  ALERT! </h3>
+
<head>
−
<p>This page is used by the judges to evaluate your team for the <a href="https://2016.igem.org/Judging/Medals">gold medal criterion for proof of concept</a>. </p>
+
<meta charset="utf-8">
 +
<meta http-equiv="X-UA-Compatible" content="IE=edge">
 +
<meta name="viewport" content="width=device-width, initial-scale=1">
 +
</head>
 +
<!-- ////////////////////// START  TOP HEADER /////////////////////// -->
 +
<head>
 +
<meta name="viewport" content="width=device-width, initial-scale=1">
 +
<link rel="stylesheet" href="http://www.w3schools.com/lib/w3.css">
 +
<style>
 +
body {
 +
  background-color:white;
 +
}
 +
.top {
 +
  position: absolute;
 +
  top: -10px;
 +
  left: 0px;
 +
  background:  #140731;
 +
  width: 100%;
 +
  height: 110px;
 +
  font-family: Corbel;
 +
  overflow: visible;
 +
}
 +
.mid {
 +
  position: absolute;
 +
  left: 150px;
 +
  width: 850px;
 +
  height: 4000px;
 +
  font-family: Corbel;
 +
  z-index:-1;
 +
}
 +
.headline {
 +
  color: #ffe;
 +
  text-align: center;
 +
  padding-top: 40px;
 +
  padding-bottom: 60px;
 +
}
 +
.header-subnav  {
 +
  background: #140731;
 +
  width: 100%;
 +
  position: absolute;
 +
  text-align: center;
 +
  margin: 0 auto;
 +
  top: 100px;
 +
  left: -30px;
 +
  font-family: Corbel;
 +
}
 +
.header-subnav li {
 +
  float: none;
 +
  display: inline-block;
 +
}
 +
.header-subnav li a {
 +
  padding: 15px 1rem;
 +
  font-size: 13px;
 +
  text-decoration: none;
 +
  color: #ffe;
 +
  text-transform: uppercase;
 +
  display: block;
 +
  font-weight: bold;
 +
  letter-spacing: 1px;
 +
  transition: all 0.35s ease-in-out;
 +
  border-radius: 4px;
 +
}
 +
.header-subnav li a.is-active {
 +
  background: rgba(250, 250, 250, 0.15);
 +
}
 +
.header-subnav li a:hover {
 +
  background: #d0d0d0;
 +
  color: #140731;
 +
  transition: all 0.35s ease-in-out;
 +
}
 +
.fixed1 {
 +
  position: fixed;
 +
  top: 13px;
 +
}
 +
.circle {
 +
  position:absolute;
 +
  left: 1160px;
 +
  top: 30px;
 +
  width: 180px;
 +
  height: 180px;
 +
  background: #140731;
 +
  -moz-border-radius: 90px;
 +
  -webkit-border-radius: 90px;
 +
  border-radius: 90px;
 +
}
 +
.left {
 +
  position: fixed;
 +
  left: 0px;
 +
  top: 175px;
 +
  font-family: Corbel;
 +
  background: rgba(250, 250, 250, 0.15);
 +
  width: 150px;
 +
  z-index:+1;
 +
}
 +
.left-tab {
 +
  background-color: rgba(250, 250, 250, 0.1);
 +
  display: block;
 +
  font-size: 20px;
 +
  color: #140731;
 +
  -webkit-transition-duration: 0.4s;
 +
  transition-duration: 0.4s;
 +
  padding-right: 40px;
 +
  padding-left: 5px;
 +
  padding-top: 5px;
 +
  padding-bottom: 5px;
 +
  z-index:+1;
 +
}
 +
.left-tab:hover {
 +
  background-color: #FF8800;
 +
  color: #140731;
 +
  font-size: 20px;
 +
  -webkit-transition-duration: 0.4s;
 +
  transition-duration: 0.4s;
 +
  padding-right: -20px;
 +
  padding-left: 5px;
 +
  border-radius: 4px;
 +
}
 +
.button {
 +
  background-color: rgba(250, 250, 250, 0.1);
 +
  display: block;
 +
  font-size: 16px;
 +
  color: #140731;
 +
  -webkit-transition-duration: 0.4s;
 +
  transition-duration: 0.4s;
 +
  padding-right: 40px;
 +
  padding-left: 5px;
 +
  padding-top: 5px;
 +
  padding-bottom: 5px;
 +
  z-index:+1;
 +
}
 +
.wrapper {
 +
  background: white;
 +
  width: 900px;
 +
  height: 500px;
 +
  border-radius: 5px;
 +
  position: relative;
 +
  overflow: hidden;
 +
  backface-visibility: hidden;
 +
}
  
 +
.frame{
 +
  background: transparent;
 +
  width: 600px;
 +
  height: 500px;
 +
  border-top: solid 45px white;
 +
  border-right: solid 5px white;
 +
  border-bottom: solid 5px white;
 +
  border-left: solid 5px white;
 +
  position: absolute;
 +
  z-index: 1;
 +
}
  
−
<p> Delete this box in order to be evaluated for this medal. See more information at <a href="https://2016.igem.org/Judging/Pages_for_Awards/Instructions"> Instructions for Pages for awards</a>.</p>
+
input[type='radio'] {
−
</div>
+
  -webkit-appearance: none;
 +
  background: #FF8800;
 +
  border-radius: 4px;
 +
  border-color: #FF8800;
 +
  width: 119px;
 +
  height: 35px;
 +
  margin: 5px 0 5px 5px;
 +
  background-size: 225px 70px;
 +
  position: relative;
 +
  left: 200px;
 +
  float: left;
 +
  display: inline;
 +
  top: 0;
 +
  border-radius: 5px;
 +
  z-index: 99999;
 +
  cursor: pointer;
 +
}
  
 +
input[type='radio']:before{
 +
  content: attr(data-tooltip);
 +
  color: black;
 +
  font-size: 20px;
 +
  font-family: Corbel;
 +
  font-weight:bold;
 +
  text-align:center;
 +
  position: absolute;
 +
  top:5px;
 +
  left:25px;
 +
}
  
 +
input[type='radio']:hover{
 +
  background: white; 
 +
  color: #FF8800;
 +
  border-color: #FF8800;
 +
}
  
 +
input[type='radio']:checked{
 +
  background: white;
 +
  border-color: #FF8800;
 +
}
 +
.tab {
 +
  margin-left: -20px;
 +
  transition: .3s ease-out;
 +
}
 +
.tab li{
 +
  background: #fff;
 +
  color: black;
 +
  width: 1000px;
 +
  height: 500px;
 +
  display: inline;
 +
  float: left;
 +
  bottom: 0;
 +
  z-index: -1;
 +
}
 +
.tab1:checked ~ ul{
 +
  transform: translateY(0);
 +
}
  
 +
.tab2:checked ~ ul{
 +
  transform: translateY(-500px);
 +
}
  
−
<div class="column full_size">
+
.tab3:checked ~ ul{
 +
  transform: translateY(-1000px);
 +
}
  
 +
.tab4:checked ~ ul{
 +
  transform: translateY(-1500px);
 +
}
  
−
<p>
+
hr1 {
−
iGEM teams are great at making things work! We value teams not only doing an incredible job with theoretical models and experiments, but also in taking the first steps to make their project real.
+
  border: 0;
−
</p>
+
  width: 80%;
 +
  color: #140731;
 +
  background-color: #140731;
 +
  height: 2px;
 +
}
  
 +
hr {
 +
  border: 0;
 +
  width: 80%;
 +
  color: #FF8800;
 +
  background-color: #FF8800;
 +
  height: 2px;
 +
}
 +
</style>
 +
</head>
  
−
<h4> What should we do for our proof of concept? </h4>
+
<script>
−
<p>
+
/* Dynamic top menu positioning
−
You can assemble a device from BioBricks and show it works. You could build some equipment if you're competing for the hardware award. You can create a working model of your software for the software award. Please note that this not an exhaustive list of activities you can do to fulfill the gold medal criterion. As always, your aim is to impress the judges!
+
*
−
</p>
+
*/
 +
var num = 110; //number of pixels before modifying styles
 +
$(window).bind('scroll', function () {
 +
    if ($(window).scrollTop() > num) {
 +
        $('.header-subnav').addClass('fixed1');
 +
    } else {
 +
        $('.header-subnav').removeClass('fixed1');
 +
    }
 +
});
  
 +
 +
//USE SCROLL WHEEL FOR THIS FIDDLE DEMO
 +
 +
 +
</script>
 +
<script>
 +
var slideIndex = 1;
 +
showDivs(slideIndex);
 +
 +
function plusDivs(n) {
 +
  showDivs(slideIndex += n);
 +
}
 +
 +
function currentDiv(n) {
 +
  showDivs(slideIndex = n);
 +
}
 +
 +
function showDivs(n) {
 +
  var i;
 +
  var x = document.getElementsByClassName("mySlides");
 +
  var dots = document.getElementsByClassName("demo");
 +
  if (n > x.length) {slideIndex = 1}
 +
  if (n < 1) {slideIndex = x.length}
 +
  for (i = 0; i < x.length; i++) {
 +
    x[i].style.display = "none";
 +
  }
 +
  for (i = 0; i < dots.length; i++) {
 +
    dots[i].className = dots[i].className.replace(" w3-border-red", "");
 +
  }
 +
  x[slideIndex-1].style.display = "block";
 +
  dots[slideIndex-1].className += " w3-border-red";
 +
}
 +
</script>
 +
 +
<body>
 +
<div class="top">
 +
<img alt="" style="position:absolute;z-index:++1;float:left;margin-top:20px;width:390px;height:80px;"  src="https://static.igem.org/mediawiki/2016/b/bb/CGU_Taiwan--logo2.jpg">
 +
<img style="position:absolute;left:1170px;top:35px;z-index:+1;width:155px;height:180px;" src="https://static.igem.org/mediawiki/2016/8/8a/CGU_Taiwan--logo9.jpg">
 +
<a name='anchor0'></a>
 +
<div class="circle"></div>
 
</div>
 
</div>
  
 +
<header class="top">
 +
<h1 class="headline">Leijuvant <small></small></h1>
 +
<ul class="header-subnav">
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan">HOME</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Achievements">ACHIEVEMENTS</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Description">PROJECT</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Software">MODELING</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices">HUMAN PRACTICES</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Team">PEOPLE</a></li>
 +
<li class="dropdown"><a href="https://2016.igem.org/Team:CGU_Taiwan/Interlab">INTERLAB</a></li>
 +
<li class="dropdown"><a href="https://2016.igem.org/Team:CGU_Taiwan/Safety">SAFETY</a></li>
 +
<li><a href="https://2016.igem.org/Team:CGU_Taiwan/Parts">PARTS</a></li>
 +
</ul>
 +
</header>
 +
 +
<div class="mid" style="top:180px;">
 +
<br>
 +
<div style="font-size:60px;color:#66B3FF;text-decoration:none;">
 +
Proof of Concept
 +
</div>
 +
<br><br>
 +
 +
<b><font size="6px">We established stable Leishmania transfectants and proved the function of
 +
promotor with hygromycin drug selection gene</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;">
 +
The promoter and the ribosomal binding site of Leishmania genome has not
 +
been elucidated yet. We selected the 5'- untranslated region of a highly expressed
 +
gene, P36, to be the promoter, RBS binding site and other extra function needed for
 +
Leishmania protein expression. We also added a hygromycin resist gene to serve as a
 +
dual functional biobrick of regulatory and selection marker. We provide the user with
 +
the regulation of protein expression and also the drug selection system that is most
 +
commonly and effectively used in Leishmania experiments.
 +
The pSB1C3-5'HYG-OVA-3'UTR was transfected into Leishmania 12-DT strain,
 +
and the transfectants were selected by hygromycin. We obtained the
 +
hygromycin-resistant Leishmania transfectants (Figure 1. B, C). In the negative control
 +
group (Figure 1. A), we could see that almost all cells were dead and the shape of
 +
Leishmania was not normal. It showed that Leishmania transfectants were resistant
 +
to high concentration of hygromycin. The function of 5’HYG was assayed more
 +
precisely in figure 2.
 +
</div><br>
 +
<img src="https://static.igem.org/mediawiki/2016/3/37/Proof1.jpeg" width=850px height=150px></img><br><br>
 +
 +
<br><br>
 +
 +
<b><font size="6px">Successfully expressed Hemagglutinin of H1N1</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;">
 +
Since we are performing immunology experiments, it is very important that the
 +
antigen is correctly expressed. We used BL21 competent cell to express the HA
 +
sequence and detect the protein by Western blot analysis.<br>
 +
The pSB1C3-J04500-HA can is checked by Western blot analysis. We successfully
 +
recognize the HA protein from Western blot analysis (approximately 62.3kd) when
 +
induced by IPTG (Figure 3.).<br><br>
 +
<img src="https://static.igem.org/mediawiki/2016/4/4e/Proof2.jpeg" width=850px height=150px></img><br><br>
 +
</div>
 +
<br><br>
 +
 +
<b><font size="6px">The immune response of Leijuvant in mice</font></b>
 +
<div style="color:black;text-decoration:none;font-size:18px;margin-left:70px;">
 +
The IgG1 antibody titer increased drastically after the second boost on the 15th day.
 +
And the antibody titer reached to peak on the 25th day (Figure 4A.). Inactivated
 +
Leishmania can achieve over 60% of the antibody titer. As for OVA-expressing
 +
inactivated Leishmania, the antibody titer can reach about 80% on the 25th day. The
 +
IgG2a antibody titer of inactivated Leishmania increased extremely on the 20th day
 +
and is significantly higher compare to Alum on the 25th day(Figure 4A.). Leijuvant is a
 +
potential bi-pathway adjuvant that can stimulate both Th1 and Th2 immune
 +
responses.<br><br>
 +
<img src="https://static.igem.org/mediawiki/2016/1/19/Proof3.jpeg" width=850px height=150px></img><br><br>
 +
<br>
 +
</div>
 +
<br><br>
  
  
 
</div>
 
</div>
  
 +
</body>
 
</html>
 
</html>

Revision as of 01:24, 20 October 2016

Leijuvant


Proof of Concept


We established stable Leishmania transfectants and proved the function of promotor with hygromycin drug selection gene
The promoter and the ribosomal binding site of Leishmania genome has not been elucidated yet. We selected the 5'- untranslated region of a highly expressed gene, P36, to be the promoter, RBS binding site and other extra function needed for Leishmania protein expression. We also added a hygromycin resist gene to serve as a dual functional biobrick of regulatory and selection marker. We provide the user with the regulation of protein expression and also the drug selection system that is most commonly and effectively used in Leishmania experiments. The pSB1C3-5'HYG-OVA-3'UTR was transfected into Leishmania 12-DT strain, and the transfectants were selected by hygromycin. We obtained the hygromycin-resistant Leishmania transfectants (Figure 1. B, C). In the negative control group (Figure 1. A), we could see that almost all cells were dead and the shape of Leishmania was not normal. It showed that Leishmania transfectants were resistant to high concentration of hygromycin. The function of 5’HYG was assayed more precisely in figure 2.





Successfully expressed Hemagglutinin of H1N1
Since we are performing immunology experiments, it is very important that the antigen is correctly expressed. We used BL21 competent cell to express the HA sequence and detect the protein by Western blot analysis.
The pSB1C3-J04500-HA can is checked by Western blot analysis. We successfully recognize the HA protein from Western blot analysis (approximately 62.3kd) when induced by IPTG (Figure 3.).





The immune response of Leijuvant in mice
The IgG1 antibody titer increased drastically after the second boost on the 15th day. And the antibody titer reached to peak on the 25th day (Figure 4A.). Inactivated Leishmania can achieve over 60% of the antibody titer. As for OVA-expressing inactivated Leishmania, the antibody titer can reach about 80% on the 25th day. The IgG2a antibody titer of inactivated Leishmania increased extremely on the 20th day and is significantly higher compare to Alum on the 25th day(Figure 4A.). Leijuvant is a potential bi-pathway adjuvant that can stimulate both Th1 and Th2 immune responses.